@article{3076828,
    title = "Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe",
    author = "Kroese, T.E. and van Hillegersberg, R. and Schoppmann, S. and Deseyne, P.R.A.J. and Nafteux, P. and Obermannova, R. and Nordsmark, M. and Pfeiffer, P. and Hawkings, M.A. and Smyth, E. and Markar, S. and Hanna, G.B. and Cheong, E. and Chaudry, A. and Elme, A. and Adenis, A. and Piessen, G. and Gani, C. and Bruns, C.J. and Moehler, M. and Liakakos, T. and Reynolds, J. and Morganti, A. and Rosati, R. and Castoro, C. and D'Ugo, D. and Roviello, F. and Bencivenga, M. and de Manzoni, G. and Jeene, P. and van Sandick, J.W. and Muijs, C. and Slingerland, M. and Nieuwenhuijzen, G. and Wijnhoven, B. and Beerepoot, L.V. and Kolodziejczyk, P. and Polkowski, W.P. and Alsina, M. and Pera, M. and Kanonnikoff, T.F. and Nilsson, M. and Guckenberger, M. and Monig, S. and Wagner, D. and Wyrwicz, L. and Berbee, M. and Gockel, I. and Lordick, F. and Griffiths, E.A. and Verheij, M. and van Rossum, P.S.N. and van Laarhoven, H.W.M. and Rosman, C. and Rütten, H. and Gootjes, E.C. and Vonken, F.E.M. and van Dieren, J.M. and Vollebergh, M.A. and van der Sangen, M. and Creemers, G.-J. and Zander, T. and Schlößer, H. and Cascinu, S. and Mazza, E. and Nicoletti, R. and Damascelli, A. and Slim, N. and Passoni, P. and Cossu, A. and Puccetti, F. and Barbieri, L. and Fanti, L. and Azzolini, F. and Ventoruzzo, F. and Szczepanik, A. and Visa, L. and Reig, A. and Roques, T. and Harrison, M. and Ciseł, B. and Pikuła, A. and Skórzewska, M. and Vanommeslaeghe, H. and Van Daele, E. and Pattyn, P. and Geboes, K. and Callebout, E. and Ribeiro, S. and van Duijvendijk, P. and Tromp, C. and Sosef, M. and Warmerdam, F. and Heisterkamp, J. and Vera, A. and Jordá, E. and López-Mozos, F. and Fernandez-Moreno, M.C. and Barrios-Carvajal, M. and Huerta, M. and de Steur, W. and Lips, I. and Diez, M. and Castro, S. and O'Neill, R. and Holyoake, D. and Hacker, U. and Denecke, T. and Kuhnt, T. and Hoffmeister, A. and Kluge, R. and Bostel, T. and Grimminger, P. and Jedlička, V. and Křístek, J. and Pospíšil, P. and Mourregot, A. and Maurin, C. and Starling, N. and Chong, I. and OMEC working group",
    journal = "EUROPEAN JOURNAL OF CANCER",
    year = "2022",
    volume = "164",
    pages = "18-29",
    publisher = "Elsevier Ireland Ltd",
    doi = "10.1016/j.ejca.2021.11.032",
    keywords = "antineoplastic agent;  fluorodeoxyglucose f 18, adrenal metastasis;  adult;  Article;  bone metastasis;  cancer radiotherapy;  cancer therapy;  chemoradiotherapy;  clinical article;  controlled study;  distant metastasis;  drug uptake;  esophageal adenocarcinoma;  esophageal squamous cell carcinoma;  esophagus cancer;  esophagus resection;  Europe;  female;  follow up;  gastrectomy;  human;  human tissue;  liver metastasis;  lung metastasis;  lymph node metastasis;  male;  metastasis;  metastasis resection;  paraaortic lymph node;  radiosurgery;  soft tissue metastasis;  stomach adenocarcinoma;  stomach cancer;  systemic therapy",
    abstract = "Background: Consensus about the definition and treatment of oligometastatic oesophagogastric cancer is lacking. Objective: To assess the definition and treatment of oligometastatic oesophagogastric cancer across multidisciplinary tumour boards (MDTs) in Europe. Material and methods: European expert centers (n = 49) were requested to discuss 15 real-life cases in their MDT with at least a medical, surgical, and radiation oncologist present. The cases varied in terms of location and number of metastases, histology, timing of detection (i.e. synchronous versus metachronous), primary tumour treatment status, and response to systemic therapy. The primary outcome was the agreement in the definition of oligometastatic disease at diagnosis and after systemic therapy. The secondary outcome was the agreement in treatment strategies. Treatment strategies for oligometastatic disease were categorised into upfront local treatment (i.e. metastasectomy or stereotactic radiotherapy), systemic therapy followed by restaging to consider local treatment or systemic therapy alone. The agreement across MDTs was scored to be either absent/poor (<50%), fair (50%–75%), or consensus (≥75%). Results: A total of 47 MDTs across 16 countries fully discussed the cases (96%). Oligometastatic disease was considered in patients with 1–2 metastases in either the liver, lung, retroperitoneal lymph nodes, adrenal gland, soft tissue or bone (consensus). At follow-up, oligometastatic disease was considered after a median of 18 weeks of systemic therapy when no progression or progression in size only of the oligometastatic lesion(s) was seen (consensus). If at restaging after a median of 18 weeks of systemic therapy the number of lesions progressed, this was not considered as oligometastatic disease (fair agreement). There was no consensus on treatment strategies for oligometastatic disease. Conclusion: A broad consensus on definitions of oligometastatic oesophagogastric cancer was found among MDTs of oesophagogastric cancer expert centres in Europe. However, high practice variability in treatment strategies exists. © 2022 The Authors"
}